Learn how tau tangles drive Alzheimer's disease and explore tools and therapies shaping the future of tau research.
10 hours ago

Yet most diagnoses still occur only after cognitive decline becomes noticeable and irreversible. Biomarkers are reshaping that reality.
2 days ago

Since 2020, Abcam has been working with an independent open-science organization, YCharOS (pronounced 'Icarus'), to verify the quality and consistency of...
2 months ago

Danaher Corporation (NYSE: DHR) ('Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the 'Transaction').
3 months ago

The Company is providing the following guidance for FY2024. Reported revenue of approximately £475 million to £525 million 1 , representing 11.3% to 13.4% CER...
4 months ago

MAPK signaling pathway. Mitogen-activated protein kinase (MAPK) cascades consist of at least three protein kinase modules that are sequentially...
2 months ago

Partnership extends Abcam's reach within in vitro diagnostics market ... Under the agreement, Cell Marque will apply its extensive IVD expertise to incorporate...
4 months ago

Abcam opens new US facility in Boston, MA ... Cambridge, UK, 13 July 2021 – Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools,...
4 months ago

Apoptosis markers can serve as valuable indicators for therapeutic interventions and regulating them can help restore the balance between cell survival and...
5 months ago

The Company is reiterating its 2024 reported revenue goals of £450 million to £525 million¹ with adjusted operating profit margins of greater than 30%. About...
3 months ago